Keywords: رازگالیل; Mechanochemistry; Kinetic resolution; CALB; Rasagiline; Green chemistry;
مقالات ISI رازگالیل (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: رازگالیل; Aging; Rasagiline; Antidepressant-like behavior; Cognition; Neuroprotection; Neurotrophic parameters;
Keywords: رازگالیل; Catechins; Theoflavin; Rasagiline; Catechol-O-methyl transferase inhibition; Phophorylated ERK1/2; Polyphenols
Keywords: رازگالیل; Rasagiline; Bladder; Dopamine; Parkinson;
Keywords: رازگالیل; ABR; auditory brainstem response; ANOVA; analysis of variance; DA; dopamine; EM; electron microscopy; FR; fractional release; Glu; glutamate; HEPES; 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid; HL; hearing loss; IHCs; inner hair cells; LOC; la
Keywords: رازگالیل; Orodispersible films; Drug printing; Individualised medicine; Rasagiline; Tadalafil; Flexographic printing;
Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22â¯cells
Keywords: رازگالیل; ER stress; Ferroptosis; Oxidative stress; Oxindole; Oxytosis; Rasagiline; ATF6; activated transcription factor 6; ARE; antioxidant response element; DMEM; Dulbecco's modified Eagle's medium; ER; endoplasmic reticulum; Grp78; 78-kDa glucose-regulated prote
Simultaneous bioanalysis of rasagiline and its major metabolites in human plasma by LC-MS/MS: Application to a clinical pharmacokinetic study
Keywords: رازگالیل; Rasagiline; Metabolites; Determination; Human plasma; LC-MS/MS;
Efficacy and tolerability of rasagiline in daily clinical use—A post marketing observational study in patients with Parkinson’s disease focusing on non-motor symptoms and QoL
Keywords: رازگالیل; Parkinson’s disease; MAO-B inhibitor; Rasagiline; Non-motor symptoms; Quality of life
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: Post-hoc analyses from the ADAGIO trial
Keywords: رازگالیل; Parkinson's disease; Rasagiline; Monotherapy;
Research ReportRasagiline prevents neurodegeneration in thiamine deficient rats-A longitudinal MRI study
Keywords: رازگالیل; Thiamine deficiency; Neurodegeneration; Neuroprotection; Magnetic resonance imaging; Rasagiline;
Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials
Keywords: رازگالیل; Parkinson; Rasagiline; Fluctuation; Bradykinesia; Entacapone; Agonist;
Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway
Keywords: رازگالیل; Clorgyline; Dopamine D2 receptors; 6-Hydroxydopamine; Parkinson's disease; Rasagiline; DA; Dopamine; MAO; Monoamine oxidase; PD; Parkinson's disease; 6-OHDA; 6-hydroxydopamine; LT; N-linoleoyl tyrosine;
Rasagiline in Parkinson's disease: A review based on meta-analysis of clinical data
Keywords: رازگالیل; Rasagiline; Azilect; Parkinson disease; Unified Parkinson Disease Rating Scale
Effects of selegiline and rasagiline on disease progression in Parkinson’s disease
Keywords: رازگالیل; Selegiline; Rasagiline; Disease modification; Clinical trials; Delayed start design
Drug interactions with selegiline versus rasagiline
Keywords: رازگالیل; Rasagiline; Selegiline; Drug interactions; MAO-B inhibition
Mitochondria, monoamine oxidase B and Parkinson’s disease
Keywords: رازگالیل; Parkinson’s disease; Monoamine oxidase; Selegiline; Rasagiline; Cell death
A critical review of evidence for preclinical differences between rasagiline and selegiline
Keywords: رازگالیل; Rasagiline; Selegiline; Parkinson therapy; Monoamine oxidase-B inhibitors; Neuroprotection; Disease modification
Effects of monoamine oxidase Type B inhibitors on motor and non-motor symptoms in Parkinson’s disease: A systematic comparison of rasagiline and selegiline
Keywords: رازگالیل; Parkinson’s disease; Pharmacotherapy; Monoamine oxidase inhibitors; Selegiline; Rasagiline; Non-motor symptoms
Bio-analytical method development and validation of Rasagiline by high performance liquid chromatography tandem mass spectrometry detection and its application to pharmacokinetic study
Keywords: رازگالیل; High performance liquid chromatography; Mass spectrometry; Rasagiline; Liquid–liquid extraction
Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease
Keywords: رازگالیل; Rasagiline; Selegiline; Parkinson’s disease; Meta-analysis
Neuropharmacology and AnalgesiaEffect of rasagiline on the molecular composition of the excitatory postsynaptic density
Keywords: رازگالیل; Rasagiline; NMDA receptor; Postsynaptic density; Neuroprotection; Rat; Parkinson's disease;
An effective novel delivery strategy of rasagiline for Parkinson's disease
Keywords: رازگالیل; Rasagiline; Parkinson; Microspheres; Neuroprotection; PET/CT; RT-PCR
The emergence of designed multiple ligands for neurodegenerative disorders
Keywords: رازگالیل; ACh; acetylcholine; A2A; adenosine receptor subtype two-A; Aβ; amyloid-beta; ACE; angiotensin converting enzyme; BDNF; brain derived neurotrophic factor; GDNF; glial derived neurotrophic factors; MAO-B; monoamine oxidase B; AChE; acetylcholinesterase; AP
Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells
Keywords: رازگالیل; Parkinson's disease; Alpha-synuclein; Rasagiline; Mitochondria; Free radicals; Neuroprotection;
Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence
Keywords: رازگالیل; compliance; adherence; persistence; Parkinson's disease; antiparkinson medications; rasagiline;
New considerations in the medical management of early Parkinson's disease: Impact of recent clinical trials on treatment strategy
Keywords: رازگالیل; Parkinson's disease; Treatment; Selegiline; Rasagiline; Pramipexole; Ropinirole; Levodopa
Validated LC–MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study
Keywords: رازگالیل; Liquid chromatography–tandem mass spectrometry; Rasagiline; Pharmacokinetics
Rapid and sensitive liquid chromatography–tandem mass spectrometry: Assay development, validation and application to a human pharmacokinetic study
Keywords: رازگالیل; Rasagiline; Human pharmacokinetics; Urine excretion; LC–MS/MS
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy
Keywords: رازگالیل; Multiple system atrophy; Striatonigral degeneration; Olivopontocerebellar atrophy; α-synuclein; Transgenic mouse; Rasagiline; Neuroprotection
Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
Keywords: رازگالیل; Rasagiline; Ladostigil; M30; A2A receptor antagonists; Dal mechanims; Adenosine; Iron chelation
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms
Keywords: رازگالیل; Parkinson's disease; Rasagiline; Tolerability; Efficacy
l-Methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action
Keywords: رازگالیل; Clorgyline; Dependence syndrome; Methamphetamine; Monoamine oxidase; Morphine; Opioid-related disorders; Progressive ratio schedule; Rasagiline; Reinforcement; Selegiline; Self-administration; Withdrawal
Rasagiline (TVP-1012): A new selective monoamine oxidase inhibitor for Parkinson's disease
Keywords: رازگالیل; rasagiline; TVP-1012; monoamine oxidase; Parkinson's disease;
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives
Keywords: رازگالیل; Disorders of the nervous system; Parkinson's disease and other neurodegenerative diseases; Parkinson's disease; Neuroprotection; Rasagiline; Propargylamine; Ladostigil; PKC; Bcl-2; Cell death; MAPK;
Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases
Keywords: رازگالیل; Alzheimer's disease; Parkinson's disease; Ladostigil (TV3326); Rasagiline; Propargylamines; Neuroprotection; Bcl-2 family proteins; PKC; MAPkinase; Monoamine oxidase; Cholinesterase; Inhibitors; Iron chelators; Amyloid precursor protein;
Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells
Keywords: رازگالیل; Rasagiline; Parkinson's disease; MAO-B; Cerebellar granule cells; Neuroprotection; Astrocyte; Synapsin;